Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Cantargia AB
Scrip Asks…What Does 2023 Hold For Biopharma? Part 8: Therapeutic Area Advances
Neuroscience and oncology fuel high hopes for therapeutic R&D progress among 90-plus surveyed biopharma industry leaders.
Cantargia Confident About Nadunolimab’s Prospects For Pancreatic Cancer
The selection of nadulonimab by the Pancreatic Cancer Action Network for its adaptive clinical trial is a strong validation of the Stockholm-based firm's compound, which is also being evaluated for lung cancer.
Ichnos Gets Going With Almirall Deal, Multiple Myeloma Bispecifics Add Sheen
Glenmark’s US-based innovation arm Ichnos delivers first licensing deal for IL-1RAP antagonist, while early data for a bispecific antibody demonstates promising activity in multiple in vitro and in vivo tumor models relative to daratumumab and magrolimab.
Stock Watch: Like Moths To The Unvalidated Flame
Leaving the validation of a drug target until the end of Phase III studies is risky, but working on the unvalidated targets identified by others is riskier still.
- Large Molecule
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.